Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1
Objectives: This study aimed to report the demographic and clinical characteristics of diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti-vascular endothelial growth factors (anti-VEGF) and provide an overview of outcomes during routine clinical practice in Türki...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2023-12-01
|
| Series: | Türk Oftalmoloji Dergisi |
| Subjects: | |
| Online Access: |
http://www.oftalmoloji.org/archives/archive-detail/article-preview/real-world-outcomes-of-ntravitreal-anti-vascular-e/63937
|
| _version_ | 1797382431904366592 |
|---|---|
| author | Uğur Yayla Mehmet Orkun Sevik Veysel Levent Karabaş Özlem Şahin Abdullah Özkaya Nursal Melda Yenerel Banu Açıkalın Öncel Fatih Bilgehan Kaplan Ecem Önder Tokuç Hatice Selen Kanar Işıl Kutlutürk Karagöz Ece Başaran Emengen Ayşe Demirciler Sönmez Aslan Aykut Utku Limon Erdinç Bozkurt Işılay Özsoy Saygın Tuğba Aydoğan Gezginaslan Özlem Aydın Öncü Esra Türkseven Kumral Nimet Yeşim Erçalık Erkan Çelik |
| author_facet | Uğur Yayla Mehmet Orkun Sevik Veysel Levent Karabaş Özlem Şahin Abdullah Özkaya Nursal Melda Yenerel Banu Açıkalın Öncel Fatih Bilgehan Kaplan Ecem Önder Tokuç Hatice Selen Kanar Işıl Kutlutürk Karagöz Ece Başaran Emengen Ayşe Demirciler Sönmez Aslan Aykut Utku Limon Erdinç Bozkurt Işılay Özsoy Saygın Tuğba Aydoğan Gezginaslan Özlem Aydın Öncü Esra Türkseven Kumral Nimet Yeşim Erçalık Erkan Çelik |
| author_sort | Uğur Yayla |
| collection | DOAJ |
| description | Objectives: This study aimed to report the demographic and clinical characteristics of diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti-vascular endothelial growth factors (anti-VEGF) and provide an overview of outcomes during routine clinical practice in Türkiye. Materials and Methods: This retrospective, real-world study included 1,372 eyes (854 patients) treated with a pro re nata protocol by 21 ophthalmologists from 8 tertiary clinics on the Asian side of the Marmara region of Türkiye (MARMASIA Study Group). Five cohort groups were established by collecting the patients’ baseline and 3, 6, 12, 24, and 36-month follow-up data, where each subsequent cohort may include the previous. Changes in best-corrected visual acuity (BCVA, approximate ETDRS letters) and central macular thickness (CMT, μm), number of visits and IVI, and rates of anti-VEGF switch and intravitreal dexamethasone implant (IDI) combination were evaluated. Results: The 3, 6, 12, 24, and 36-month cohorts included 1372 (854), 1352 (838), 1185 (722), 972 (581), and 623 (361) eyes (patients), respectively. The mean baseline BCVA and CMT were 51.4±21.4 letters and 482.6±180.3 μm. The mean changes from baseline in BCVA were +7.6, +9.1, +8.0, +8.6, and +8.4 letters, and in CMT were -115.4, -140.0, -147.9, -167.3, and -215.4 μm at the 3, 6, 12, 24, and 36-month visits (p<0.001 for all). The median cumulative number of anti-VEGF IVI was 3.0, 3.0, 5.0, 7.0, and 9.0, respectively. The overall anti-VEGF switch and IDI combination rates were 18.5% (253/1372 eyes) and 35.0% (480/1372 eyes), respectively. Conclusion: This largest real-life study of DME from Türkiye demonstrated BCVA gains inferior to randomized controlled trials, mainly due to the lower number of IVI. However, with the lower baseline BCVA and higher IDI combination rates in our cohorts, these gains were relatively superior to other real-life study counterparts. |
| first_indexed | 2024-03-08T21:06:18Z |
| format | Article |
| id | doaj.art-366bac1877524f1aba6d51d5c33e7bbc |
| institution | Directory Open Access Journal |
| issn | 1300-0659 2147-2661 |
| language | English |
| last_indexed | 2024-03-08T21:06:18Z |
| publishDate | 2023-12-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türk Oftalmoloji Dergisi |
| spelling | doaj.art-366bac1877524f1aba6d51d5c33e7bbc2023-12-22T13:05:04ZengGalenos YayineviTürk Oftalmoloji Dergisi1300-06592147-26612023-12-0153635636810.4274/tjo.galenos.2023.5624913049054Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1Uğur Yayla0Mehmet Orkun Sevik1Veysel Levent Karabaş2Özlem Şahin3Abdullah Özkaya4Nursal Melda Yenerel5Banu Açıkalın Öncel6Fatih Bilgehan Kaplan7Ecem Önder Tokuç8Hatice Selen Kanar9Işıl Kutlutürk Karagöz10Ece Başaran Emengen11Ayşe Demirciler Sönmez12Aslan Aykut13Utku Limon14Erdinç Bozkurt15Işılay Özsoy Saygın16Tuğba Aydoğan Gezginaslan17Özlem Aydın Öncü18Esra Türkseven Kumral19Nimet Yeşim Erçalık20Erkan Çelik21 Sağlık Bilimleri Üniversitesi, Derince Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, Kocaeli, Türkiye Marmara Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İstanbul, Türkiye Kocaeli Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Kocaeli, Türkiye Marmara Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İstanbul, Türkiye Memorial Şişli Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Fatih Sultan Mehmet Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Fatih Sultan Mehmet Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Kocaeli Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Kocaeli, Türkiye Sağlık Bilimleri Üniversitesi, Kartal Dr. Lütfi Kırdar Şehir Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Kocaeli Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Kocaeli, Türkiye Sağlık Bilimleri Üniversitesi, Fatih Sultan Mehmet Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Marmara Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Ümraniye Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sağlık Bilimleri Üniversitesi, Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Kliniği, İstanbul, Türkiye Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Anabilim Dalı, Sakarya, Türkiye Objectives: This study aimed to report the demographic and clinical characteristics of diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti-vascular endothelial growth factors (anti-VEGF) and provide an overview of outcomes during routine clinical practice in Türkiye. Materials and Methods: This retrospective, real-world study included 1,372 eyes (854 patients) treated with a pro re nata protocol by 21 ophthalmologists from 8 tertiary clinics on the Asian side of the Marmara region of Türkiye (MARMASIA Study Group). Five cohort groups were established by collecting the patients’ baseline and 3, 6, 12, 24, and 36-month follow-up data, where each subsequent cohort may include the previous. Changes in best-corrected visual acuity (BCVA, approximate ETDRS letters) and central macular thickness (CMT, μm), number of visits and IVI, and rates of anti-VEGF switch and intravitreal dexamethasone implant (IDI) combination were evaluated. Results: The 3, 6, 12, 24, and 36-month cohorts included 1372 (854), 1352 (838), 1185 (722), 972 (581), and 623 (361) eyes (patients), respectively. The mean baseline BCVA and CMT were 51.4±21.4 letters and 482.6±180.3 μm. The mean changes from baseline in BCVA were +7.6, +9.1, +8.0, +8.6, and +8.4 letters, and in CMT were -115.4, -140.0, -147.9, -167.3, and -215.4 μm at the 3, 6, 12, 24, and 36-month visits (p<0.001 for all). The median cumulative number of anti-VEGF IVI was 3.0, 3.0, 5.0, 7.0, and 9.0, respectively. The overall anti-VEGF switch and IDI combination rates were 18.5% (253/1372 eyes) and 35.0% (480/1372 eyes), respectively. Conclusion: This largest real-life study of DME from Türkiye demonstrated BCVA gains inferior to randomized controlled trials, mainly due to the lower number of IVI. However, with the lower baseline BCVA and higher IDI combination rates in our cohorts, these gains were relatively superior to other real-life study counterparts. http://www.oftalmoloji.org/archives/archive-detail/article-preview/real-world-outcomes-of-ntravitreal-anti-vascular-e/63937 anti-vegfdiabetic macular edemaintravitreal injectionreal-life studyroutine clinical practice |
| spellingShingle | Uğur Yayla Mehmet Orkun Sevik Veysel Levent Karabaş Özlem Şahin Abdullah Özkaya Nursal Melda Yenerel Banu Açıkalın Öncel Fatih Bilgehan Kaplan Ecem Önder Tokuç Hatice Selen Kanar Işıl Kutlutürk Karagöz Ece Başaran Emengen Ayşe Demirciler Sönmez Aslan Aykut Utku Limon Erdinç Bozkurt Işılay Özsoy Saygın Tuğba Aydoğan Gezginaslan Özlem Aydın Öncü Esra Türkseven Kumral Nimet Yeşim Erçalık Erkan Çelik Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 Türk Oftalmoloji Dergisi anti-vegf diabetic macular edema intravitreal injection real-life study routine clinical practice |
| title | Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 |
| title_full | Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 |
| title_fullStr | Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 |
| title_full_unstemmed | Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 |
| title_short | Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 |
| title_sort | real world outcomes of intravitreal anti vascular endothelial growth factor treatment for diabetic macular edema in turkiye marmasia study group report no 1 |
| topic | anti-vegf diabetic macular edema intravitreal injection real-life study routine clinical practice |
| url |
http://www.oftalmoloji.org/archives/archive-detail/article-preview/real-world-outcomes-of-ntravitreal-anti-vascular-e/63937
|
| work_keys_str_mv | AT uguryayla realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT mehmetorkunsevik realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT veyselleventkarabas realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT ozlemsahin realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT abdullahozkaya realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT nursalmeldayenerel realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT banuacıkalınoncel realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT fatihbilgehankaplan realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT ecemondertokuc realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT haticeselenkanar realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT isılkutluturkkaragoz realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT ecebasaranemengen realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT aysedemircilersonmez realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT aslanaykut realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT utkulimon realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT erdincbozkurt realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT isılayozsoysaygın realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT tugbaaydogangezginaslan realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT ozlemaydınoncu realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT esraturksevenkumral realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT nimetyesimercalık realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 AT erkancelik realworldoutcomesofintravitrealantivascularendothelialgrowthfactortreatmentfordiabeticmacularedemainturkiyemarmasiastudygroupreportno1 |